Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Novartis aims to offload eye care unit to Bausch + Lomb for up to $2.5 billion

By Brian Buntz | July 3, 2023

Novartis logoNovartis has agreed to sell ophthalmology assets to Bausch + Lomb for an upfront payment of $1.75 billion, with potential milestone payments of up to $750 million. The total value of the deal could reach $2.5 billion. Novartis expects the deal to improve their focus more on higher-margin drugs.

Under the terms of the deal, Bausch + Lomb will get Novartis’ Xiidra, a treatment for dry eye disease, as well as two experimental products: libvatrep (formerly SAF312), an experimental treatment for chronic ocular surface pain with Phase 2b test results expected later this year. It will also receive AcuStream, a medical device being for delivery of topical eye medications.

Xiidra generated more than $487 million in 2022 revenue.

In addition to Xiidra, Bausch + Lomb already has a presence in the dry eye disease market, bagging FDA-approval for a drug called Meibo in May. The two drugs are expected to complement each other, targeting different aspects of the dry eye disease cycle. Bausch + Lomb financed the deal through debt from J.P. Morgan. The deal will likely close by the end of this year.

Novartis and Bausch + Lomb deal part of a broader trend

The deal reflects appetite for M&A strengthening product offerings, especially in specialized areas like ophthalmology. For acquirers, marketed products leverage commercial infrastructure and gain complementary treatments. For companies divesting, it concentrates efforts on higher priorities, gains milestones, and supports continuity of care.

In June, Novartis also agreed to spend up to $3.5 billion to acquire Chinook.

In the first half of 2023, pharma M&A deals have surged as companies look for pipeline growth ahead of patent expirations. While the prospect of increasing regulatory scrutiny may scuttle some deals, the volume of deals remains fairly robust.

The second quarter of 2023 had a mix of large strategic M&A deals and smaller targeted acquisitions. While megadeals of over $10 billion were sparse relative to the beginning of the year, mid-sized transactions dominated.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

This image shows the logos of GE HealthCare and Nihon Medi-Physics.
GE HealthCare to fully own Nihon Medi-Physics
This is the logo of Johnson & Johnson.
Johnson & Johnson brings in billions from remaining Kenvue stake
bruker logo
Bruker to acquire NanoString business
Vertex Pharmaceuticals to acquire Alpine Immune Sciences in $4.9B deal
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE